Printer Friendly


 SALT LAKE CITY and PHILADELPHIA, Dec. 14 /PRNewswire/ -- NPS Pharmaceuticals, Inc. (NPS) and SmithKline Beecham (SB)(NYSE: SBH) announced today that they have signed an agreement to collaborate on the discovery, development and commercialization of novel, orally active drugs for the treatment of osteoporosis. The collaboration will focus on NPS technology in calcium receptors.
 Under the terms of the agreement, both parties will commit significant scientific resources to the collaborative research program. NPS will receive payments totaling $6 million, and upon achievement of certain milestones will be eligible for further cash payments and research funding. In addition, S.R. One, SB's venture capital affiliate, is making an equity investment of $7 million in NPS, S.R. One's second investment in NPS to date.
 SB will have exclusive worldwide rights to products derived from the collaboration for the treatment of osteoporosis and related bone and mineral disorders, and will pay royalties to NPS on product sales. NPS will have the option to copromote products with SB in the U.S., and under certain conditions may obtain exclusive worldwide rights to products not commercialized by SB.
 Osteoporosis is an age-related disorder which affects 200 million people worldwide, although only a fraction of patients are treated. The disease is characterized by a decrease in bone mass and is responsible for approximately 1.5 million fractures annually in the U.S. alone. With the aging of the population and improvements in early diagnosis, the number of patients actively treated is expected to double in the nest 25-35 years.
 Hunter Jackson, Ph.D., chairman and CEO of NPS, commented, "SmithKline Beecham is a very well suited partner for NPS in this field. They are experienced in the development and marketing of osteoporosis therapies and have an outstanding research group dedicated to bone disease. We share significant commitment to exploit this novel technology and believe strongly in its potential to create a major breakthrough in this area of growing medical need."
 Dr. George Poste, chairman, research and development, at SB, said "research at NPS Pharmaceuticals into the role of calcium receptors in osteoporosis complements our own efforts in this field. This agreement is further evidence of our resolve to establish wide-ranging collaborations in support of small companies with demonstrated expertise in leading-edge technologies."
 SmithKline Beecham -- one of the world's leading healthcare companies -- discovers develops, manufactures and markets human pharmaceuticals, over-the-counter medicines and health-related consumer products, veterinary products and clinical laboratory services.
 NPS Pharmaceuticals, Inc. is a privately-held Salt Lake City based, development stage pharmaceutical company. NPS combines a novel focus on ion-related drug targets with a non-traditional program in discovery of drug leads from selected natural products. In addition to osteoporosis, other current therapeutic targets of the company's technologies include hyperparathyroidism and neurological disorders such as stroke, epilepsy, and pain.
 -0- 12/14/93
 /CONTACT: Hunter Jackson, Ph.D., of NPS Pharmaceuticals, 801-583-4939, or Richard Koenig of SmithKline Beecham, 215-751-3415/

CO: NPS Pharmaceuticals, Inc.; SmithKline Beecham ST: Utah, Pennsylvania IN: MTC SU: JVN

JL-CM -- NE002 -- 3572 12/14/93 10:29 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 14, 1993

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters